Pancreatic Cancer Research

ResearcherUniversity of FreiburgActive in the last 2 years

Melanie Boerries

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3670-0602; OpenAlex author ID A5009680251, A5121030335. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: 3 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: 3 papers · 2026: 3 papers

Papers 12

  1. Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations. Co-author DOI 10.1038/s41392-025-02563-7↗
  2. Immunomodulatory impact of PTPN11 /SHP2-based vertical RAS-MAPK pathway inhibition in pancreatic cancer Co-author DOI 10.64898/2026.05.23.727401↗
  3. Improvement of Gemcitabine Treatment of Pancreatic Cancer by the Addition of All- trans Retinoic Acid and Identification of Vitamin A and Pentraxin 3 as Potent… Co-author DOI 10.64898/2026.08.16.26359923↗
  4. Response to PD-1 inhibition in MMRd/MSS pancreatic ductal adenocarcinoma: the relevance of parallel testing. Co-author DOI 10.1007/s00432-025-06334-3↗
  5. 17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing? Co-author DOI 10.1016/j.esmogo.2025.100218↗
  6. Adaptive resistance to SHP2-based vertical RAS-pathway inhibition in pancreatic cancer involves multifaceted routes towards dedifferentiation Co-author DOI 10.1101/2025.09.09.25335395↗
  7. Integrated Analysis of Cell-Free DNA and Novel Protein Biomarkers for Stratification and Therapy Monitoring in Stage IV Pancreatic Cancer: A Preliminary Study. Co-author DOI 10.3390/diagnostics15010049↗
  8. Spatially confined sub-tumor microenvironments in pancreatic cancer. Co-author DOI 10.1016/j.cell.2021.09.022↗
  9. Perioperative cell-free mutant KRAS dynamics in patients with pancreatic cancer Co-author DOI 10.1093/bjs/znaa116↗
  10. Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer. Co-author DOI 10.1186/s12885-020-07736-x↗
  11. Identification and Validation of a Diagnostic and Prognostic Multi-Gene Biomarker Panel for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3389/fgene.2018.00108↗
  12. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Co-author DOI 10.1038/ncb3513↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dietrich Alexander Ruess · 4 shared papers, 2025–2026 · strength 0.84
  2. Uwe A. Wittel · 5 shared papers, 2018–2026 · strength 0.79
  3. Wilfried Reichardt · 4 shared papers, 2017–2026 · strength 0.68
  4. Asma Y. Alrawashdeh · 3 shared papers, 2025–2026 · strength 0.63
  5. Philipp Hafner · 3 shared papers, 2025–2026 · strength 0.63
  6. Saskia Hussung · 4 shared papers, 2018–2024 · strength 0.59
  7. Ralph Fritsch · 4 shared papers, 2018–2024 · strength 0.59
  8. Heiko Becker · 2 shared papers, 2025–2026 · strength 0.47
  9. Michael Quante · 2 shared papers, 2025–2026 · strength 0.47
  10. Julian Hipp · 2 shared papers, 2021 · strength 0.26
  11. Heike Luise Pahl · 1 shared paper, 2025 · strength 0.26
  12. Sarah Niessen · 1 shared paper, 2026 · strength 0.22
  13. Sophia Chikhladze · 1 shared paper, 2026 · strength 0.22
  14. Carola Focke · 1 shared paper, 2026 · strength 0.22
  15. Friederike Inga Nollmann · 1 shared paper, 2026 · strength 0.20
  16. Oliver Schilling · 1 shared paper, 2026 · strength 0.20
  17. Xun Chen · 1 shared paper, 2025 · strength 0.19
  18. Sylvia Timme‐Bronsert · 1 shared paper, 2021 · strength 0.14
  19. Sandra Elisabeth Fischer · 1 shared paper, 2021 · strength 0.10
  20. Joan Miguel Romero · 1 shared paper, 2021 · strength 0.10
  21. Rama Khokha · 1 shared paper, 2021 · strength 0.10
  22. Barbara T. Grünwald · 1 shared paper, 2021 · strength 0.10
  23. Nikolina Radulovich · 1 shared paper, 2021 · strength 0.10
  24. Kazeera Aliar · 1 shared paper, 2021 · strength 0.10
  25. Grainne Mary O'Kane · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.